Evaluation of serum parathyroid hormone-related peptide in hyperthyroid patients
Version of Record online: 28 SEP 2010
© 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation
European Journal of Clinical Investigation
Volume 41, Issue 1, pages 93–97, January 2011
How to Cite
Giovanella, L., Suriano, S., Keller, F., Borretta, G. and Ceriani, L. (2011), Evaluation of serum parathyroid hormone-related peptide in hyperthyroid patients. European Journal of Clinical Investigation, 41: 93–97. doi: 10.1111/j.1365-2362.2010.02385.x
- Issue online: 8 DEC 2010
- Version of Record online: 28 SEP 2010
- Received 28 July 2010; accepted 26 August 2010
- Graves’ disease;
- ionized calcium;
- parathormone-related peptide
Eur J Clin Invest 2010; 41 (1): 93–97
Background Hypercalcemia occurs in 10–20% of patients with hyperthyroidism, but its pathogenesis is still unclear.
Aim To evaluate changes in parathyroid hormone-related peptide (PTH-rP) concentration in hyperthyroid patients compared with healthy controls.
Methods We studied PTH-rP, parathormone (PTH) and ionized calcium levels in 153 hyperthyroid patients, and 89 control subjects. These variables were revaluated after attainment of euthyroidism with the antithyroid drug carbimazole for 6 months in a subgroup of 47 patients.
Results Pretreatment PTH-rP and ionized calcium level were significantly higher in hyperthyroid patients than in controls, whereas an opposite trend occurred for PTH. All parameters normalized after carbimazole therapy.
Conclusion Untreated hyperthyroid patients exhibited a significant elevation in serum ionized calcium and PTH-rP and a significant reduction in serum PTH levels when compared with healthy controls. Our data favoured the hypothesis of a direct involvement of PTH-rP in the pathogenesis of hypercalcemia in hyperthyroid patients.